Bridge Neurotech Taps Butterfly Ultrasound Tech for Non-Invasive BCI Development

  • Bridge Neurotech emerged from stealth in October 2026, focusing on non-invasive brain-computer interfaces (BCIs) using ultrasound technology.
  • Butterfly Network will license its Ultrasound-on-Chip™ technology to Bridge for BCI development under a multi-year agreement.
  • Bridge's first human research study is now enrolling participants in Redwood City, California.
  • The deal includes payments to Butterfly for technology access, development milestones, and hardware purchases.

This partnership signals growing interest in non-invasive BCIs, leveraging advances in ultrasound and AI to potentially treat neurological conditions and expand human capabilities. Butterfly's Ultrasound-on-Chip™ technology could become a foundational component in the next wave of BCI development, while Bridge's approach may challenge traditional invasive methods. The deal underscores the convergence of semiconductor innovation and neuroscience in healthcare.

Technology Validation
Whether Bridge's functional ultrasound imaging (fUSI) platform can successfully decode brain activity non-invasively.
Market Expansion
The pace at which non-invasive BCIs could broaden access to brain-computer interface applications beyond surgical options.
Commercialization Timeline
How quickly Butterfly and Bridge can transition from research to commercial products under their partnership.